---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011218"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:47:49.384053+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q2 net loss $0.19/sh; Phase 1b PD study fully enrolled, data by Q4 2025

## Summary
- Phase 1b of GT-02287 in Parkinson's reached target enrollment in Q2 2025 with 16 patients; up to 20 total.
- Functional and biomarker analysis from 90-day dosing expected in Q4 2025; extension request submitted.
- Net loss per share $0.19 vs $0.42 YoY; R&D spend down to $2.8M on grant income and credit.
- Cash $6.7M as of June 30; July 2025 public offering raised ~$7.1M net, extending runway past Phase 1b.
- IND submission to FDA for GT-02287 expected by year-end 2025 to enable US Phase 2 expansion.

## SEC filing metadata
- accession: 0001558370-25-011218
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/0001558370-25-011218-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837025011218/ganx-20250812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011218
- JSON: https://secwatch.observer/filing/0001558370-25-011218.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011218.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.